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Abstract: Recent development of tumor resistance to paclitaxel presents a major problem to cancer treatment. An unset-
tled controversy in the cancer chemotherapy field, however, is whether caspases play a prominent role in paclitaxel-
induced death in tumors. Previous studies suggest that cleavage of caspase-3 is not instrumental for the execution of death 
in tumors treated with paclitaxel, while other reports indicate that caspase-dependent pathways may be critical for pacli-
taxel cytotoxicity. In this study, we investigated the role of caspase-3 in breast and lung tumor cell line sensitivity to pacli-
taxel. Clonogenic survival and live/dead viability-assays, together with enzymatic activity and cell proliferation assays, 
reveal that the levels of paclitaxel-induced caspase-3 enzymatic activity in tumor cells correlate directly with tumor sensi-
tivity to the drug. We observed a 2-fold increase in caspase-3 activity in 4T1-Luc breast tumor cells, but a 3-fold and 4-
fold decrease in A549 and A427 lung tumor cell lines, respectively. Together, our results suggest that caspase-activation 
and activity levels are not only key determinants of paclitaxel-induced death in tumors but also serve as good indicators 
for tumor susceptibility to paclitaxel therapy. Our studies also indicate that within clinically relevant doses of paclitaxel, 
the ability to rid tumor populations of dormant tumor cells controls the rate of tumor recurrence.  
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INTRODUCTION 
  More than thirty-eight years after its isolation from the 
bark of the Pacific Yew tree, paclitaxel has become the first 
clinically relevant representative of a novel class of antican-
cer drugs used to treat a wide variety of patients suffering 
from breast, lung, head, neck, and ovarian cancer [1-10].
 
However, recent development of paclitaxel resistance by 
tumor cells is worrisome and unsettling for clinicians since 
this affects efficacy of therapy and presents a major obstacle 
for survival of cancer patients. Drug resistance by tumors 
also complicates the development of potent cancer treat-
ments. Although current knowledge of the factors contribut-
ing to drug resistance phenotype has increased significantly 
[11,12], the roles of downstream targets of cell death, such 
as caspase 3 & 7, in tumor sensitivity to paclitaxel therapy 
have not been fully explored. Given their requisite role in 
apoptosis, caspases are potentially attractive targets for can-
cer treatment. Elucidating the factors regulating caspase ac-
tivation is therefore crucial to understanding how tumors 
manipulate these pivotal death effectors and to identify novel 
molecular targets and strategies for improving current ther-
apy. 
  In this study, we report a framework in which differential 
activity of caspase-3 in lung versus breast tumor cell lines 
controls tumor sensitivity and resistance to paclitaxel. We 
found that lung tumor cells, with repressed caspase-3 activ-
ity, were more resistant to paclitaxel than breast tumor cells. 
Thus, our findings point to an underappreciated role of 
caspases in tumor resistance to drug and support other stud 
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ies suggesting that targeting caspase activity is crucial for 
improving the potency of chemotherapeutic agents. 
MATERIALS AND METHODS 
Cell Culture  
  The human non-small cell lung carcinoma lines, A549 & 
A427 were obtained from American Type Culture Collection 
(Manassas, VA, USA) and maintained in basic medium as 
described [13]. In addition, mammary tumor cell line, 4T1-
Luc, was obtained from American Type Culture Collection 
(Manassas, VA) and maintained as described [14].
  After 
growing to 100% confluence, cells were trypsinized (0.5 mL 
trypsin in 5 mL PBS) and incubated for 5 -10 min. The cells 
were then harvested by low speed centrifugation, washed in 
1 mL media and seeded at 3 X 10
4cells per 200 L of me-
dium per well in a 96-well plastic plate (Nunc Inc. Roches-
ter, NY). A portion of cells (1 X 10
5 cells/well) was also 
grown overnight on Lab Tek 8-chamber slides (Nunc Inc. 
Rochester, NY) for caspase-activity and live/dead assays.  
Cell Proliferation Assay  
  The effect of paclitaxel on tumor cell growth was evalu- 
ated using Cell Titer 96®Aqueous One Solution Cell Prolif- 
eration Assay (Promega). This assay permits the detection of  
metabolic activity of proliferating cells without the required  
solubilization steps in the MTT assay. Briefly, 24 h drug- 
treated cells were cultured in a 37˚C humidified incubator  
for 2 h with 20 L of CellTiter96®Aqueous One Solution  
Reagent containing tetrazolium compound [3-(4, 5-dimethyl- 
thiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 
2H-tetrazolium salt; MTS] and an electron coupling reagent,  
phenazine ethosulfate (PES). The absorbance per well was  
measured at 490 nm using a micro-plate reader (Perkin   
Elmer Wallac Victor™ 1420 Multilabel Counter).  122    The Open Biochemistry Journal, 2008, Volume 2  Odonkor and Achilefu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Breast and lung cancer tumor cell lines exhibit differential susceptibility to micromolar doses of paclitaxel at equal drug ex-
posure time. 
Cell viability was determined by a modified MTT assay. After 24-h drug exposure with indicated concentrations, cells were incubated with 
20 l of MTS reagent for 2-h. Absorbance values were measured at 490 nm. Experiments were done in triplicate for each cell type, with ap-
propriate controls. The half maximal effective concentration (EC50) of paclitaxel for each cell type was determined by nonlinear regression 
analysis using GraphPad Prism Software® (version 4.0 for windows, San Diego, CA). Data represent normalized mean values. (A) Nanomo-
lar concentrations of paclitaxel have little effect on tumor cell viability especially at lower concentrations. However a dose response is ob-
served in both tumor cell types, with A427 cells showing slightly increased sensitivity than A549-cells at higher nanomolar drug concentra-
tions (500 nm and 1000 nm).Open circles represent negative control, crosses and diamonds represent positive control, black rectangles repre-
sent samples. (B) EC50 for A549 cells was determined to be 22.5 μM. (C) EC50 for A427 was determined to be 12.5 μM and (D) EC50 for 
4T1-Luc was determined to be 8.5 μM. At high drug doses > 40 μM, no significant difference in tumor cell line response to paclitaxel is ob-
served. However, clear differences in cell type sensitivity to drug dosage is observed at concentrations < 20 μM. Of the 3 tumor cell lines, 
A549 and A427 show low sensitivity to the drug at low concentrations, with 4T1-Luc cells appearing to be the most sensitive in this dose 
range. (E) Anti-proliferative effect of paclitaxel is enhanced in 4T1-Luc cells, but not in A427 and A549 cells at high drug doses. Prolifera-
tion of tumor cells after 24-hour drug treatment was analyzed by MTS assay (Molecular Probes), as described in methods section. Experi-
ments were done twice in triplicates. N=6. At concentrations  10 μM, a drastic reduction in the number of proliferating cells was observed in 
4T1-luc, in comparison with A549 and A427 cells which showed significant cell proliferation. (F) 4T1-luc tumor cells show increased aggre-
gated and clustered colony formation. Clonogenic survival assay was performed to evaluate the behavioral response of tumor cells to an ex-
tended duration of drug exposure. A time course study was performed to determine colony formation at a fixed drug concentration (12.5 μM) 
over varying exposure times (2- 14 days). Each data point was derived from the results of at least three independent experiments. N= 9. Data 
show mean ± SEM of three experiments, each in triplicate. Relative to untreated controls, a time dependent-decline in the number of colonies 
formed was observed in 4T1-luc cells, but not in A549 or A427 cells (not shown). In these latter cell lines, cells were more dispersed and very 
few aggregated colonies (cell clusters consisting of more than 100-cells) were observed. (G) 4T1-luc cells form colony aggregates in a dose-
dependent fashion, relative to A549-cells which show reduced cell colonies at higher drug concentrations. Overall, however, more proliferat-
ing A549 cells than proliferating 4T1-luc cells were present at higher concentrations.  Caspases and Tumor Resistance to Paclitaxel  The Open Biochemistry Journal, 2008, Volume 2    123 
Live-Dead Viability and Clonogenic Survival Assays 
  Cell viability and integrity after drug treatment was as-
sessed by two assays. With the live-dead viability kit (Invi-
trogen), drug-treated cells were incubated with ethidium ho-
modimer (EthD-1) for the last 45 min of the drug exposure 
period. After this treatment, the media was removed and 
slides were prepared for microscopy by mounting with pro-
long gold antifade® reagent (Invitrogen, Molecular Probes). 
For clonogenic survival assay, drug-treated cells were cul-
tured in a 37˚C humidified incubator for 10 days to allow 
colony formation. Drug exposure times varied from 2 to 14 
days for time course study. Cells were then fixed with 
methanol, stained with solution containing 20% methanol 
and 0.5% crystal violet, and clusters made up of 100-cells 
were counted as surviving colonies. The percentage of sur-
viving colonies relative to untreated cells was determined by 
the proportion of colonies produced from cells after drug 
treatment. Plating efficiency was 80% ± 10%.  
Caspase-3 Activity Assay 
  To quantify the levels of basal and induced caspase-3 
protein and corresponding activity in different tumor cell 
lines, we used a fluorometric enzymatic assay, EnzChek® 
Caspase-3 (Molecular Probes, Eugene, OR). Cell extracts 
from paclitaxel-treated (25 M) and untreated A549, A427 
and 4T1-Luc were treated with final substrate concentration 
of 200 μM and incubated at room temperature for 1 h. Fluo-
rescence was measured with a micro plate reader using exci-
tation at 360± 40nm, and emission at 460 ± 40 nm. Appro-
priate controls were performed to determine background 
fluorescence of the substrate. A standard AMC-substrate 
curve was used to quantify the levels of enzyme-cleaved 
substrate from the measured fluorescence values.  
Statistical Analysis 
  Statistical analysis was performed using the Student’s t-
test  and nonlinear regression analysis in GraphPad Prism 
Software® (version 4.0 for windows, San Diego, CA). 
RESULTS 
High Concentrations of Paclitaxel Delineate the Differen-
tial Susceptibility of Non-Small Cell Lung Carcinoma 
and Metastatic Breast Cancer Cells to Chemotherapy 
  Studies of the human non-small cell lung carcinoma cell 
lines, A549-T12 and A549-T24, show that while these pacli-
taxel resistant cells are cultured and maintained in nanomolar 
levels of drug, the parental A549-cell line from which they 
are derived is, in contrast, sensitive to nanomolar drug doses 
[15-20]. To test the ability of nanomolar- concentrations of 
drug to inhibit cell proliferation, we investigated the viability 
of the A549 and A427cell lines after exposure to 1- 1000 nM 
of paclitaxel using a modified MTT assay [19,21].
 We ob-
served that 24 h treatment of A549 and A427-cells with con-
centrations   200 nM did not impede cell viability. Cells 
showed a minor response at concentrations  500 nM, with 
A427 being slightly more susceptible than A549-cells in the 
500 t0 1000 nM range (Fig. 1A). Overall, proliferation of 
either cell line was not affected by nanomolar concentrations 
of paclitaxel. However, increasing paclitaxel doses to the 
micromolar scale remarkably decreased proliferation of 
A549 and A427 cells. The half maximal effective concentra-
tion (EC-50) for these cells was determined to be 22.5 μM 
and 12.5 μM, respectively (Fig. 1B and C). In addition, we 
measured the response of the 4T1-luc cell-line to equivalent 
micromolar drug concentrations. In contrast to A549 and 
A427-cells, 4T1-luc cells showed a strong dose response 
with EC-50 of 8.5 μM (Fig. 1D). At concentrations >40 μM, 
all three cell lines succumbed to death without distinct be-
havioral differences. However, disparate susceptibility of the 
three cell lines was pronounced at a dose range of 10 – 25 
μM. While the anti-proliferative effect of paclitaxel was en-
hanced in 4T1-Luc cells, A427 and A549 cells were rela-
tively less affected by the drug (Fig. 1E).  
  The relatively higher number of persistent proliferative 
cells in A549 and A427-cells suggests that both tumor cell 
lines potentially have an intrinsic resistance to paclitaxel. To 
further assess the behavioral response differences between 
the lung and breast tumor cell lines, we performed clono-
genic survival assays, where tumor cells were treated with 
varying concentrations of the drug for an extended period (2-
14 days). A time dependent-decline in the number of 4T1-luc 
cells, relative to the untreated controls, was observed (Fig. 
1F). Although all three cell lines showed survival dose re-
sponse, 4T1-luc tumor cells formed more aggregated and 
clustered colonies. In contrast, A549 and A427 cells ap-
peared more dispersed, with less aggregated colonies (i.e. 
one or two clusters made up of more than 100-cells) (Fig. 
1G). This suggests that 4T1-luc cells perhaps respond more 
to prolonged drug therapy by forming aggregates while 
A549 cells appear to resist paclitaxel treatment by spreading 
over the plate surface. The differences in chemotherapeutic 
response among the 3 cell lines clearly point to the underly-
ing differences in their resistance mechanisms to paclitaxel 
[22-24]. 
Paclitaxel Induces Distinct Death Phenotypes in Breast 
and Lung Carcinoma Cell Lines 
  Although it is fairly well known that most tumor cells 
undergo paclitaxel-induced apoptotic death, it is equally well 
established that paclitaxel induces other non-apoptotic pro-
grammed cell death mechanisms in different tumor cell types 
[20,21,25]. To ascertain and distinguish between apoptotic 
and non-apoptotic death, we used a Live/Dead® Viability 
assay to evaluate the quintessential cellular features of death 
such as plasma membrane blebbing, DNA fragmentation, 
and cell shrinking. We particularly examined drug-treated 
cells for the presence of fragmented nuclei and compromised 
plasma membranes as indicators of death. We observed a 
dose-dependent fragmentation of nuclear DNA as well as 
damage to the cell membrane. This phenotype was highly 
pronounced in 4T1-luc tumor cells with extensive fragmen-
tation at 50 μM and 25 μM of drug, visualized as red punc-
tate dots in dead cells stained by EthD-1 (Fig. 2, A-F). Very 
few live cells were observed at these concentrations and cells 
had a mix of necrotic and apoptotic characteristics. Nonethe-
less, the extent of membrane disintegration and nuclear dam-
age in 4T1-luc cells was more moderate at 12.5 μM and 6.25 
μM of paclitaxel (Fig. 2C & D). Like 4T1-luc cells, A549 
cells showed dose-dependent DNA fragmentation, but with 
less damaged cell membranes (Fig. 3, A-F). Moreover, dead 
cells had fewer and less dispersed punctate nuclear frag-
ments (Fig. 3A, insert). Interestingly, we observed a few 124    The Open Biochemistry Journal, 2008, Volume 2  Odonkor and Achilefu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Paclitaxel induces nuclear fragmentation and cell death in 4T1-Luc tumor cell lines.  
The extent of DNA damage observed in tumor cells was dose dependent. Arrows point to fragmented nuclei. Inserts highlight nuclear frag-
ments and damaged DNA within cells. Scale bar indicates 90 μm. Cell morbidity was determined by Live-Dead Viability Assay. Drug treated 
cells were incubated with ethidium homodimer (EthD-1), which stains fragmented nuclei of dead cells. EthD-1 dye can only penetrate cells 
with compromised membranes and emits red fluorescence (ex/em - 495 nm/ 635 nm) on binding to nucleic acids. Exclusion of the dye by 
intact membrane of live cells distinguishes dead cells from live ones. (A – F) - Apoptosis in 4T1-Luc cells. Cells treated with high paclitaxel 
doses, 50 μM (A) and 25 μM (B), show extensive nuclear fragmentation and damaged membranes. (C) At 12.5 μM and (D) 6.25 μM, moder-
ate nuclear fragmentation is observed. (E) Reflects background fluorescence from negative control cells. (F) Apoptotic induction in positive 
control (ethanol-treated) cells. Wavy black line traces boundary of damaged cell membrane. 
mitotic cells among the apoptotic A549 cell population, 
which were immobilized at the mitotic phase in the presence 
of paclitaxel. (Fig. 3A, D & F). The absence of this distinct 
population of cells in 4T1-luc cells clearly highlights differ-
ent death response mechanisms in the two tumor cell lines. 
Previous studies reported that paclitaxel suppressed microtu-
bule dynamics and disrupted the functioning of the mitotic 
spindle [26-29], suggesting a slow cell cycle progression at 
the metaphase/anaphase checkpoint that eventually induces 
cell death. The features in A549-cells fit perfectly with this 
pattern, albeit, we also observed a mix of apoptotic mor-
phologies in this cell line. Our results demonstrate that 4T1-Caspases and Tumor Resistance to Paclitaxel  The Open Biochemistry Journal, 2008, Volume 2    125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). A549 tumor cells exhibit both apoptotic and mitotic morphology in response to paclitaxel treatment. Arrows point to frag-
mented nuclei. Inserts and boxed regions highlight fragmented nuclear DNA and mitotic cells. These distinct populations of mitotic cells were 
not observed in 4T1-luc tumors. Scale bar indicates 90 μm. Cell death was determined by Live-Dead Viability Assay as described. Exclusion 
of EthD-1 dye by intact membrane of live cells distinguishes dead cells from live ones. Images are shown in red and grey channels. (A – F) - 
Cell death in A549 cells. Fragmented nuclei are visible in cells treated with high paclitaxel doses, 50 μM (A) and 25 μM (B), as well as in 
cells treated with moderate doses, 12.5 μM (C) and 6.25 μM (D). (E) No dead populations are observed in untreated cells; mitotic cells are 
visible in the grey channel. In contrast to the morphology of 4t1-luc tumor cells, mitotic proliferating A549 cells may contribute to A549 tu-
mor resistance at low doses of paclitaxel. (F) Apoptotic induction in positive control (ethanol-treated) cells. 
luc breast tumor cells respond to paclitaxel by initiating ex-
tensive nuclear fragmentation and inducing both necrotic and 
apoptotic forms of death. On the other hand, paclitaxel-
induced death in A549 cells occurs partly through interfer-
ence with cell cycle progression, thus, pointing to different 
phases of drug-induced apoptosis in the two tumor cell lines.  
Paclitaxel Induces a 2-Fold Increase in Caspase-3 Activ-
ity in 4T1-Luc Cells but a 3-Fold and 4-Fold Decrease in 
A549 and A427 Tumor Cell Lines, Respectively  
  Based on reports that somatic mutations of caspase-3 
gene in human cancers cause selective inactivation of cyste-
inyl proteinases to compromise apoptotic death [28-31], we 
hypothesized that differences in the intrinsic and drug-
induced activity of effector caspases contribute to the acute 
paclitaxel-induced death response in 4T1-luc versus the be-
nign response in A549 and A427 tumors. We predicted that 
4T1-luc cells would have relatively higher basal and drug-
induced caspase-3 activity than A549 or A427 tumor cells. 
We found that while all 3-lines showed some levels of basal 
enzymatic activity, A427-cells exhibited the least activity 
with 40 M of cleaved substrate, followed by A549-cells 
with 54 M of cleaved substrate, and then 4 T1-Luc cells, 
with 68 M of substrate (Fig. 4A). A decrease in activity in 
the presence of a caspase-3 inhibitor corroborated the speci-
ficity of the reaction. On measuring caspase-3 activity in 126    The Open Biochemistry Journal, 2008, Volume 2  Odonkor and Achilefu 
extracts from drug-treated cells, we found increased activity 
in 4T1-luc cells but a decrease in A549 and A427-cells (Fig. 
4B). This suggests that while 4T1-luc cells activate caspase-
3 on exposure to drug, A549 and A427 cells somehow re-
press caspase-3 activation. In contrast to the drug-treated 
4T1-luc cells that showed a two-fold increase in caspase-3 
activity in comparison to basal activity levels, A549 and 
A427 showed approximately a 3-fold and 4-fold decrease in 
enzymatic activity, respectively, relative to basal levels (Fig. 
4C). This result provides evidence that increased activation 
of caspase-3 confers sensitivity of 4T1-1uc cells to the drug, 
whereas repressed caspase-3 activation potentially accounts 
for the resistance of A549 and A427 cells to paclitaxel. 
DISCUSSION 
  Research on paclitaxel-resistance in A549 tumor cell 
lines reveals that the P-glycoprotein efflux pump, the known 
mediator of multi-drug resistance phenotype, plays no major 
role in resistance in this cell line [30,31]. In addition, al-
though paclitaxel-induced tubulin gene mutations and altera-
tions in total tubulin content have been reported to limit tu-
mor cell cycle progression, these observations give a partial 
account of how tumors overcome drug cytotoxicity [32,33]. 
Moreover, an unsettled controversy in the cancer chemother-
apy field is whether caspases feature prominently in pacli-
taxel-induced non-apoptotic and apoptotic forms of death 
and what the implications are for tumor cell resistance to 
paclitaxel [2,23,25,34-37]. We explored this issue further by 
determining whether the basal and drug-induced activity 
levels of caspase-3 underlies the differences in susceptibility 
of breast and lung tumor cell lines to paclitaxel.  
  Our study reveals that, relative to the lung tumor cell 
lines examined, the breast tumor cells are less resistant to 
drug, and require about 2.5 fold less drug to reach the half-
maximal effective concentration for killing cells. In contrast 
to studies emphasizing the disruptive effect of nanomolar 
concentrations of paclitaxel on microtubule dynamics in tu-
mor cells [15,16], we observed no significant changes in 
either breast or lung tumor growth at nanomolar drug con-
centrations. However, at micromolar levels of paclitaxel 
treatment, clear differences in breast and lung tumor sensi-
tivity nanomolar scale were evident. While nanomolar con-
centrations of drug may impact tubule dynamics and mitosis, 
the differences in our findings suggest that the global effects 
on tumor survival at such low drug concentrations are less 
threatening to the tumor cells. In preclinical trials, detectable 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Tumor cell lines exhibit differential basal and drug-induced caspase-3 activity. The intrinsic and drug-induced caspase-3 activ-
ity of 3-cell lines were determined by a fluorimetric enzymatic assay that measures cleavage of a caspase-3 specific substrate, Z-DEVD-
AMC, where Z represents a benzyloxycarbonyl group, and AMC, 7-amino-4-methylcoumarin. The substrate fluoresces weakly in the UV 
range (Ex/Em~330/390 nm) but yields strong blue-fluorescent product (Ex/Em ~ 342/441 nm) upon proteolytic cleavage and allows continu-
ous monitoring of the activity of caspase-3 and its related proteases in cell extracts. A standard AMC-substrate curve was used to quantify 
the levels of enzyme-cleaved substrate from the measured fluorescence values. To confirm that the observed fluorescence signal was due to 
the activity of caspase-3-like proteases, control treatments were incubated with 10 M of a reversible caspase-3 inhibitor, Ac-DEVD, prior to 
treating cells with the substrate. Experiments were performed twice in triplicate. N= 6. Data show mean ± SEM of 2 experiments done in 
triplicate. 
(A) While all 3-lines showed some level of basal enzymatic activity, A427-cells showed the least activity with 40 M of cleaved substrate, 
followed by A549-cells, with 54 M of cleaved substrate. 4 T1-Luc cells showed the highest levels of activity with 68 M of cleaved sub-
strate. A decrease in activity in the presence of a caspase-3 inhibitor confirms the specificity of the reaction. The underlying difference in 
caspase-3 activity may account for the observed resistance patterns after drug exposure. (B) Paclitaxel induces differential caspase-3 activity 
in tumor cell lines. Whereas 4T1-Luc cells showed an increase in levels of cleaved product (120 M, 60% of added substrate) after exposure 
to drug, A549 and A427-cells showed a decrease in the levels of cleaved product, with 20 M and 11 M, respectively, of cleaved substrate. 
This suggests that while 4T1-luc cells activate caspase-3 on exposure to drug, A549 and A427 cells somehow repress caspase-3 activation. 
(C) In comparison to basal enzymatic activity levels, paclitaxel induces a two-fold increase in caspase-3 activity in 4T1-luc cells as measured 
by increased levels of cleaved substrate. In contrast, A549 and A427 show approximately a 3-fold (2.7) and 4-fold (3.64) decrease in enzy-
matic activity, respectively. This increased activation of caspase-3 underlies the sensitivity of 4T-1uc cells to drug, whereas, repressed 
caspase-3 activation potentially accounts for the resistance of A549 and A427 cells to paclitaxel.  Caspases and Tumor Resistance to Paclitaxel  The Open Biochemistry Journal, 2008, Volume 2    127 
plasma concentrations of paclitaxel is dependent on the ini-
tial dose, mode of delivery and pharmacokinetics, and have 
varied from 0.05 nM to 0.1 μM, after IP paclitaxel micro-
spheres treatment [38]. 
  Although it has been argued that over time, cells treated 
with nanomolar concentrations of paclitaxel accumulate in-
tracellular drug levels to the micromolar scale [16], our re-
sults highlight crucial differences in the temporal and behav-
ioral response of tumors bombarded immediately with mi-
cromolar levels versus tumors experiencing a gradual in-
crease in drug levels. In the former scenario, the marked sen-
sitivity of tumors to drug suggests that a sudden influx of 
drug at high concentrations affords tumors little time to initi-
ate a counteractive response. However, in the latter scenario, 
the absence of a pronounced effect on tumor growth suggests 
that within the time window where intracellular concentra-
tions build up to micromolar levels, tumor cells are able to 
recoup many drug resistant processes to combat the toxic 
effects of paclitaxel. Thus, breast and lung tumor cells evade 
death at low paclitaxel concentrations. 
  The apparent difference in the phenotypic outcomes of 
low versus high drug concentrations has significant implica-
tions for cancer therapy. For one, it delineates the importance 
of using micromolar drug concentrations within the clini-
cally achievable plasma concentrations (<10μM) for therapy 
[2,38-41]. These high concentrations probably limit the time 
window in which tumor tumors are able to regroup and resist 
drug action. High drug concentrations also afford distinc-
tions in tumor susceptibility to drugs and enhance the poten-
tial to kill dormant cancer cells that are hibernating in cell 
cycle arrest within tumor populations. A note of caution 
here, however, is that it is of clinical importance to study 
whether the use of higher drug concentrations aggravates 
sides effects such as inflammation and neurotoxicity. 
  The variation in chemotherapeutic response of breast and 
lung carcinoma cell lines clearly point to underlying differ-
ences in their resistance mechanisms to paclitaxel. While 
previous studies using colon, B-lymphoma and lung cancer 
cells have argued against the key role of effector caspases in 
paclitaxel-induced cytotoxicity [17,25], our findings evoke a 
direct correlation between caspase-3 activation and tumor 
susceptibility to paclitaxel. The observation that lung tumor 
cells which are more resistant to paclitaxel exhibit as much 
as a four-fold decrease in caspase-3 activity points to an un-
derappreciated role of caspases in tumor resistance to drug. 
In contrast to other reports in support of caspase-independent 
response to paclitaxel at nanomolar levels and different tu-
mor cell lines [25,42], the positive response found in this 
study could be attributed to the use of micromolar levels of 
drug and breast/lung tumor cells. Although nanomolar levels 
of paclitaxel did not allow good delineation of tumor suscep-
tibility, they induced different tumor behavioral responses in 
cells than do high drug concentrations. Our results also sup-
port the concept of tumor cell line specificity of caspase-
regulated resistance to drug. 
  An interesting challenge arising from this study relates to 
deciphering factors that account for the differential activity 
of caspases in different tumor lines. The differences in 
cleavage mechanisms of caspases in different tumors or the 
presence of endogenous inhibitors preventing caspase-3 ac-
tivity in resistant tumor cell lines are probably involved. 
Some studies have shown that constitutive levels of known 
endogenous inhibitors of caspases, such as XIAPs, do not 
correlate with paclitaxel resistance patterns in tumors 
[35,43]. Combined with our study, it is obvious that other 
mechanisms or yet unidentified inhibitors of caspase-3 play a 
key role in preventing enzyme activation in some tumor 
cells.  
CONCLUSION 
  In summary, the functional status of caspases plays a key 
role in the response of tumors to drugs. Specifically, nano-
molar concentrations of paclitaxel may not be optimal for 
killing tumors but provide invaluable information about 
caspase-mediated response of different tumors to the drug. 
Even in tumor cell lines that subsequently develop resistance 
to treatment, the activity levels of caspases determines sus-
ceptibility of the tumors to paclitaxel. Considering that all 
the tumor cell lines examined responded positively at mi-
cromolar concentration, a delicate balance between side ef-
fects and benefits of the drug at high concentrations is 
needed to optimize cancer cell death. The potential to use 
tumor-specific drug carriers to increase the local concentra-
tion of drugs in tumors relative to healthy tissues would im-
prove treatment outcome. 
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